middle.news
How Lumos Diagnostics Is Accelerating FebriDx® Adoption Ahead of FDA Decision
2:42pm on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
How Lumos Diagnostics Is Accelerating FebriDx® Adoption Ahead of FDA Decision
2:42pm on Thursday 29th of January, 2026 AEDT
Key Points
FebriDx® sales increased 4.3 times year-on-year in Q2 FY26
FDA CLIA waiver application progressing with positive feedback, decision expected by March 2026
100% Medicare reimbursement coverage secured across all US jurisdictions
BARDA-supported paediatric study underway with 90 patients enrolled
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE